U.S. markets close in 3 hours 16 minutes
  • S&P 500

    3,636.26
    -18.78 (-0.51%)
     
  • Dow 30

    29,085.59
    -175.22 (-0.60%)
     
  • Nasdaq

    10,778.38
    -24.55 (-0.23%)
     
  • Russell 2000

    1,656.71
    +0.82 (+0.05%)
     
  • Crude Oil

    78.16
    +1.45 (+1.89%)
     
  • Gold

    1,639.60
    +6.20 (+0.38%)
     
  • Silver

    18.44
    -0.04 (-0.22%)
     
  • EUR/USD

    0.9586
    -0.0026 (-0.27%)
     
  • 10-Yr Bond

    3.9700
    +0.0920 (+2.37%)
     
  • GBP/USD

    1.0692
    +0.0009 (+0.09%)
     
  • USD/JPY

    144.8020
    +0.1220 (+0.08%)
     
  • BTC-USD

    19,362.13
    +345.48 (+1.82%)
     
  • CMC Crypto 200

    444.10
    -15.04 (-3.28%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

See Why Alzamend Neuro Stock Is Rallying On Thursday

·1 min read
  • Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application.

  • Today's response provides a path for its planned clinical development of AL002, the Company says.

  • AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

  • The FDA agreed to Alzamend's proposed combined Phase 1/2 study.

  • Alzamend will file the IND by the end of November and initiate the clinical trial of AL002 in Q1 of 2022.

  • Related: Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate.

  • Price Action: ALZN stock increased 33.5% at $3.04 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.